Amgen starts two critical late-stage trials for weight loss drug MariTide
MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and Eli Lilly.
Amgen (NASDAQ:AMGN) Enters Late-Stage Testing on Weight Loss Drug
We know that weight loss drugs have been big winners for the companies that produce them. And now, biotech stock Amgen (AMGN) looks to get in
Amgen enters Maritime, launching 2 late-stage obesity trials for MariTide
Amgen’s most advanced obesity asset MariTide is entering Maritime—that is, a phase 3 program that includes two freshly launched trials. | Amgen’s most advanced obesity asset MariTide is entering Maritime—that is,
Amgen begins late-stage trials for obesity therapy
Amgen (NASDAQ:AMGN) has announced the beginning of two Phase 3 studies for its weight loss candidate MariTide as the company aims to take a slice of a burgeoning obesity drug market dominated by Eli Lilly (LLY) and Novo Nordisk (NVO).
Amgen starts late-stage studies of MariTide
Elsewhere in the obesity space — Amgen has initiated Phase 3 trials of its obesity drug MariTide, one in overweight and obese people without diabetes and another one for people with diabetes.
Amgen Starts Final-Stage Studies of Its Monthly Obesity Drug
Amgen Inc. launched two final-stage studies of its monthly obesity treatment, a closely watched drug that would compete with blockbuster weight-loss medicines from Eli Lilly & Co. and Novo Nordisk A/S.
Amgen (NasdaqGS:AMGN) Declares US$2 Dividend Per Share For Q2 2025
Amgen (NasdaqGS:AMGN)'s recent affirmation of a $2.38 per share dividend for Q2 2025 could reflect investor confidence and ...
Amgen Stock: Why I Still Rate It A 'Buy'
Amgen released financial results for the 4th quarter of 2024. Check out why I continue to cover AMGN stock with a 'Buy' ...
7AMGN : Behind the Scenes of Amgen's Latest Options Trends
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Amgen's whale ...
Amgen (AMGN) Up 2.9% Since Last Earnings Report: Can It Continue?
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Drugmaker Amgen to invest $200 million in India site, CEO says
U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further ...
Amgen price target raised to $294 from $275 at BofA
BofA raised the firm’s price target on Amgen (AMGN) to $294 from $275 and keeps an Underperform rating on the shares. For the last several ...
Zacks.com on MSN2d
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
Amgen (AMGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...
FiercePharma3d
Sinusitis data from Amgen, AZ's Tezspire spark 'best-in-disease' talk amid Sanofi, GSK competition
Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...